**Relationships of High-sensitive C-reactive Protein and P-wave Dispersion in Lone Atrial Fibrillation**

Li-Hui Zheng, Yan Yao, Ling-Min Wu, Kui-Jun Zhang, Shu Zhang

State Key Laboratory of Cardiovascular Disease, Clinical EP Laboratory and Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China

**Background:** Current evidence links atrial fibrillation (AF) to the inflammation. Inflammatory indexes such as high-sensitive C-reactive protein (hs-CRP) have been related to the development and persistence of AF. However, the role of inflammation in the atrial electrophysiological remodeling indexed by P-wave dispersion (Pd) remains unclear.

**Methods:** The study consisted of 71 patients with lone paroxysmal AF (AF group) and 71 age- and gender-matched controls of paroxysmal supraventricular tachycardia without history of AF (control group). Electrocardiography, Pd, hs-CRP, and other clinical characteristics were compared between the two groups.

**Results:** There was no significant difference between the two groups regarding age, gender, hyperlipidemia, etc. Compared to controls, left atrial diameter (44 ± 7 vs 39 ± 7 mm), Pd (49 ± 13 vs 26 ± 8 ms), and hs-CRP (2.17 [1.46–2.89] vs 1.12 [0.74–1.41] mg/L) were increased (P < 0.05), respectively. Linear regression identified hs-CRP as an independent correlation of Pd level both in the total population and the AF group (r = 0.464 and 0.313; P < 0.001, respectively). Multiple logistic regression revealed hs-CRP as an independent determinant of AF (odds ratio [OR] =15.430, 95% confidence interval: 6.031–39.476; P <0.001). Further adjusted for Pd, both Pd and hs-CRP were independent predictors for AF, but the OR for hs-CRP in predicting AF has been attenuated from 15.430 to 6.246.

**Conclusions:** In lone AF, Pd and plasma hs-CRP concentration are inter-associated and related to AF. The interaction between hs-CRP and AF may be mediated by Pd, suggesting an important role of inflammation in the atrial electrophysiological remodeling predisposing to AF.

**Key words:** Atrial Fibrillation; High-sensitive C-reactive Protein; Inflammation; P-wave Dispersion

**INTRODUCTION**

Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Although the exact pathophysiology of AF remains unclear, it is accepted that the initiation and maintenance of AF require both a trigger and a susceptible substrate. The trigger is mainly the ectopic beats or repetitive foci from pulmonary veins or atrium. The heterogeneous atrial effective period, atrial enlargement, and atrial fibrosis constitute the main process of atrial remodeling, which provide the substrate of atrial inhomogeneous conduction predisposing AF. P-wave dispersion (Pd) is defined as the difference between the maximum and the minimum P-wave duration calculated on a 12-lead surface electrocardiogram (ECG). Prolonged Pd has been proposed an independent predictor of atrial remodeling and development of AF in patients with various cardiovascular diseases.\(^1\) An increasing body of evidences has demonstrated that inflammation plays an important role in the initiation and perpetuation of AF. Increased inflammatory markers (mainly high-sensitivity C-reactive protein [hs-CRP]) are increased in AF and could predict new-onset AF and AF recurrence after cardioversion or catheter ablation.\(^10\)–\(^14\)

Little is known about the relationship between inflammation and atrial remodeling in AF. Only one previous study evaluated the relationship between hs-CRP and Pd and demonstrated that hs-CRP and Pd are interrelated and associated with AF.\(^15\) However, that study included population with hypertension predisposing to hs-CRP and Pd elevation and the arrhythmia.\(^16\)–\(^17\) The purpose of this study was to investigate the association between inflammation (as indexed by hs-CRP) and atrial electrophysiological remodeling (as indexed by Pd) and their associations in lone AF patients without hypertension and structural heart disease.
METHODS

Patients

Between June 2008 and July 2009, 71 consecutive patients with symptomatic paroxysms of lone AF (AF group) were recruited. All the patients in AF group had the paroxysms of AF lasting for <48 h. Furthermore, no patients had received electrical cardioversion before. Seventy-one consecutive subjects of paroxysmal supraventricular tachycardia without history of AF matched for age and gender (control group) [Table 1].

We aimed to include a population with lone AF and no comorbid conditions with hypertension and various structural heart diseases. The following conditions were also excluded, including hepatic or renal dysfunction, acute or chronic pulmonary embolism, chronic obstructive pulmonary disease, thyroid dysfunction and established diagnosis of diabetes mellitus or sleep apnea. In addition, none of the participants had any history of inflammatory or infection disease or recent (within the last 4 weeks) trauma or surgery; none was under treatment with nonsteroidal anti-inflammatory or corticosteroids drugs. For the clear identification of the onset of P-wave deflection on the 12-lead ECG, patients with permanent pacemaker implantation, bundle branch block, abnormal serum electrolyte or ventricular pre-excitation were also excluded.

All AF patients discontinued all anti-arrhythmic drugs treatment at least for 5 half-lives prior to enrollment in the study. Informed written consent was obtained from all patients, and this study was approved by the Ethics Committee of Fuwai Hospital and clinical investigations are conducted according to the principles expressed in the Declaration of Helsinki.

Clinical characteristics

Patients were interviewed, and records were reviewed to determine past medical history, medications, and 12-lead ECG for P<sub>d</sub> assessment, a complete echocardiography and plasma hs-CRP levels determination. The body mass index (BMI) was calculated as body weight (kg) divided by the square of the height (m) at the time of the admission. After admission, left atrial diameter (LAD), left ventricular end-diastolic diameter (LVEDD), and left ventricular ejection fraction (LVEF) were determined by echocardiography within 3 days.

Chemical laboratory analyses

Venous blood samples were collected from the antecubital vein in the morning upon admission. Plasma hs-CRP concentration was determined in heparinized plasma with a commercially available enzyme-linked immunoturbidimetric assay (Orion Diagnostica, Finland). The measurement range and detection limit of this test were 0.25–10.00 mg/L and 0.25 mg/L, respectively.

Measurement of P-wave dispersion

The standard 12-lead ECG was recorded at a 50 mm/s paper speed and 1 mV/cm standardization. Recordings were performed during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers. P-wave on all derivations was measured during sinus rhythm and spontaneous breathing in the supine position. All P-wave duration was measured blindly by two experienced observers.

Statistical analysis

Continuous data are presented as mean ± standard deviation (SD) and categorical variables as percentage. The Kolmogorov–Smirnov statistic was used to test for any deviation from normality and the variables with nonnormally distributed scores were presented as median plus interquartile range. Because of the large range in hs-CRP, results of its log are also reported. The AF group was compared with the control group using the two-sample t-test for independent samples when dealing with approximately normally distributed scores were presented as median plus interquartile range. Because of the large range in hs-CRP, results of its log are also reported. The AF group was compared with the control group using the two-sample t-test. Linear regression was performed to evaluate the independent relationship of hs-CRP and P<sub>d</sub> in the total population and

### Table 1: Characteristics of the study population with AF and control group

| Variables                                      | AF group (n = 71) | Control group (n = 71) | P   |
|------------------------------------------------|------------------|------------------------|-----|
| Age (years)                                    | 57 ± 8           | 54 ± 11                | 0.560 |
| Male (n (%)                                     | 51 (71.8)        | 53 (74.6)              | 0.610 |
| Smoking (n (%))                                 | 29 (40.8)        | 27 (38.0)              | 0.340 |
| Hyperlipidemia (n (%))                         | 11 (15.5)        | 12 (16.9)              | 0.450 |
| BMI (kg/m²)                                    | 25.5 ± 2.1       | 24.8 ± 2.5             | 0.047 |
| Systolic blood pressure (mmHg)                 | 131 ± 15         | 127 ± 15               | 0.540 |
| Diastolic blood pressure (mmHg)                | 80 ± 13          | 77 ± 12                | 0.410 |
| Heart rate (beats/min)                         | 81 ± 18          | 76 ± 15                | 0.290 |
| Fasting glucose (mmol/L)                       | 5.02 ± 0.63      | 4.85 ± 0.64            | 0.470 |
| Serum creatinine (µmol/L)                      | 80.6 ± 15.7      | 79.2 ± 12.6            | 0.290 |
| hs-CRP (mg/L)                                   | 2.17 (1.46–2.89) | 1.12 (0.74–1.41)       | 0.001 |
| Log (hs-CRP)                                    | 0.31 ± 0.21      | 0.02 ± 0.18            | 0.001 |
| LAD (mm)                                       | 44 ± 7           | 39 ± 7                 | 0.000 |
| LVEDD (mm)                                     | 51 ± 4           | 49 ± 5                 | 0.009 |
| LVEF (%)                                       | 62 ± 6           | 63 ± 7                 | 0.570 |
| P<sub>max</sub> (ms)                            | 119 ± 17         | 102 ± 15               | 0.010 |
| P<sub>mean</sub> (ms)                          | 70 ± 23          | 76 ± 17                | 0.120 |
| P<sub>d</sub> (ms)                              | 49 ± 13          | 26 ± 8                 | 0.000 |

AF: Atrial fibrillation; BMI: Body mass index; hs-CRP: High sensitive C-reactive protein; LAD: Left atrial diameter; LVEDD: Left ventricular end diastolic diameter; LVEF: Left ventricular ejection fraction; P<sub>max</sub>: Maximum P-wave duration; P<sub>mean</sub>: Minimum P-wave duration; P<sub>d</sub>: P-wave dispersion.
the AF group. In addition to hs-CRP, each of other clinical and laboratory variables were also analyzed by multivariate linear regression in the total population.

Multivariate logistic regression analysis was used to determine the effects of various baseline clinical and laboratory variables in AF. A stepwise forward selection algorithm was applied to select determinants of AF, with criteria of \( P < 0.05 \) for inclusion and \( P \geq 0.05 \) for removal from the model to screen covariates in the multivariate analysis. The variables included in the multivariate model were age, gender, smoking, hyperlipidemia, BMI, systolic blood pressure, diastolic blood pressure, heart rate, fasting glucose, serum creatinine, hs-CRP, LAD, LVEDD, LVEF and \( P_d \). Adjusted odds ratio (OR) and 95\% confidence interval (CI) were calculated. \( P < 0.05 \) is considered statistically significant. All statistical analyses were performed using SPSS software version 13.0 (SPSS, Inc., Chicago, IL, USA).

**Results**

**Clinical characteristics**

In patients with lone AF, the mean age was 57 ± 8 years, and 71.8\% were male. They had their arrhythmia for a median duration of 3 years (2–7 years) prior to inclusion in this study. Patients with AF had received a variety of medications for AF, including warfarin in 3 patients, aspirin in 10, β blocker in 15, calcium channel blocker in 6, propranolol in 10, and amiodarone in 5. The subjects in the control group were not taking any routinely cardiovascular medications before enrollment. The clinical and echocardiographic characteristics of the study population are presented in Table 1. Apart from the matched age and gender, no significant differences were observed between two groups with reference to their blood pressure, heart rate, fasting glucose, and serum creatinine \((P > 0.05)\). Compared to the control group, the AF patients showed a larger LVEDD and LAD \((P < 0.05)\), respectively. There was no statistically significant difference between two groups in LVEF \((P > 0.05)\).

**Comparisons of high-sensitive C-reactive protein and P-wave dispersion between the two groups**

Levels of hs-CRP were significantly higher in the AF group than in the control group. The median hs-CRP in the AF group was 2.17 mg/L, compared to 1.12 mg/L in the control group \((P < 0.05)\). The mean log (hs-CRP) values were significantly related to AF \((r = 0.313, P < 0.001)\) and hs-CRP \((r = 15.430, 95\% CI: 6.031–39.476, P < 0.001)\) were associated with AF. After adjustment of \( P_d \), both \( P_d \) \((OR = 1.213, 95\% CI: 1.123–1.310, P < 0.001)\) and hs-CRP \((OR = 6.246, 95\% CI: 2.280–17.115, P < 0.001)\) were the independent predictors for AF, but the OR for hs-CRP in predicting AF has been attenuated from 15.430 to 6.246 \([Table 4]\).

**Multivariate predictors of P-wave dispersion**

Regression analysis of hs-CRP level and \( P_d \) as a continuous variable revealed a positive relationship between the two variables in the total study population \((r = 0.464, P < 0.001)\) and in the AF group \((r = 0.313, P < 0.001)\). Multivariate regression analysis identified hs-CRP level as an independent positive correlate of \( P_d \) \((t = 6.278, P < 0.001)\). Other independent factors included age \((t = 2.040, P = 0.030)\), BMI \((t = 2.910, P = 0.004)\), LAD \((t = 3.718, P < 0.001)\), and LVEDD \((t = 2.226, P = 0.028)\). The gender, smoking, hyperlipidemia, systolic blood pressure, diastolic blood pressure, heart rate, fasting glucose, serum creatinine, and LVEF showed no significant relationship with \( P_d \) and were discarded from the regression model \([Table 2]\).

**Univariate and multivariate predictors of atrial fibrillation**

In univariate logistic analysis, BMI, hs-CRP, LAD, LVEDD, and \( P_d \) were significantly related to AF \((P < 0.05)\), respectively \([Table 3]\).

The following variables including age, gender, smoking, hyperlipidemia, BMI, systolic blood pressure, diastolic blood pressure, heart rate, fasting glucose, serum creatinine, hs-CRP, LAD, LVEDD, and LVEF were analyzed using multivariate logistic regression analyses. The results demonstrated that LVEDD \((OR = 1.189, 95\% CI: 1.063–1.332, P = 0.003)\) and hs-CRP \((OR = 15.430, 95\% CI: 6.031–39.476, P < 0.001)\) were associated with AF. After adjustment of \( P_d \), both \( P_d \) \((OR = 1.213, 95\% CI: 1.123–1.310, P < 0.001)\) and hs-CRP \((OR = 6.246, 95\% CI: 2.280–17.115, P < 0.001)\) were the independent predictors for AF, but the OR for hs-CRP in predicting AF has been attenuated from 15.430 to 6.246 \([Table 4]\).

**Discussion**

This study demonstrated that lone AF patients have a higher level of hs-CRP and \( P_d \) compared to age and gender-matched.

| Variables           | \( t \)  | \( P \)  |
|---------------------|--------|--------|
| Age                 | 2.040  | 0.030  |
| Male                | 0.858  | 0.392  |
| Smoking             | −1.682 | 0.095  |
| Hyperlipidemia      | 1.258  | 0.211  |
| BMI                 | 2.910  | 0.004  |
| Systolic blood pressure | 1.435  | 0.154  |
| Diastolic blood pressure | 0.636  | 0.526  |
| Heart rate          | −0.146 | 0.884  |
| Fasting glucose     | 1.258  | 0.211  |
| Serum creatinine    | 0.736  | 0.463  |
| hs-CRP              | 6.278  | 0.000  |
| LAD                 | 3.718  | 0.000  |
| LVEDD               | 2.226  | 0.028  |
| LVEF                | −0.543 | 0.588  |

\( P_d \): P-wave dispersion; BMI: Body mass index; hs-CRP: High-sensitive C-reactive protein; LAD: Left atrial diameter; LVEDD: Left ventricular end diastolic diameter; LVEF: Left ventricular ejection fraction.
controls. Hs-CRP and P₉ were positively correlated and in association with AF. The interaction between hs-CRP and AF may be mediated by P₉, suggesting an important role of inflammation in the atrial electrophysiological remodeling predisposing to AF.

P-wave dispersion represents a noninvasive ECG marker that may reflect the prolongation of intraatrial and interatrial conduction time, as well as the discontinuous inhomogeneous propagation of sinus impulses.[1] Previous studies have reported that AF is associated with increased P₉ in various clinical settings, including patients with hypertrophic cardiomyopathy,[3] atrial septal defect,[4] rheumatic mitral stenosis,[5] acute myocardial infarction,[6] and post-surgery of coronary artery bypass.[7] In addition, P₉ is associated with AF in patients with hyperthyroidism[8] or chronic obstructive pulmonary disease.[9] In patients with lone AF, P₉ was also increased and was associated with AF,[1] which is consistent with the present study. Thus, P₉ has become a valuable ECG index for atrial remodeling and proven its predicting utility for AF.

Recently, an increasing body of evidence links AF to the inflammatory state. Frustaci et al.[10] demonstrated a high prevalence of inflammatory infiltrates, myocyte necrosis, and fibrosis in atrial biopsies of patients with lone AF. In a canine sterile pericarditis model,[11] AF is associated with initiation of inflammation. Hs-CRP, acting as the major inflammatory index, whose relationship with AF has been intensely studied. Plasma hs-CRP level is increased in AF.[10] In a community-based population,[10] increased hs-CRP levels at baseline independently predicted newly detected AF. Furthermore, baseline hs-CRP levels could predict the risk of new-onset AF after cardiac surgery,[11] and predict AF recurrence after successful electrical cardioversion[12] or catheter ablation.[13] In addition, hs-CRP has been independently related to pro-thrombotic state in AF.[14] Moreover, elevated hs-CRP levels have been reported 2 weeks after successful cardioversion of AF.[20] These studies suggested a pathogenetic role, rather than a consequence for inflammation in AF.

It has been speculated that the process of inflammation and oxidative stress are interrelated and contribute to the atrial remodeling.[21] Notably, atrial remodeling represents the major pathophysiological substrate in AF. Thus, it may be speculated that the association between inflammation and AF may be mediated by atrial remodeling. However, the interrelationship of inflammation with atrial remodeling, as indexed by hs-CRP and P₉, and their association with AF has not been fully analyzed. In one recent study, Tsioufis et al.[15] reported that hs-CRP and P₉ are interrelated and associated with AF. However, in that study, the enrolled population were all hypertensive subjects. The exact relationship between hs-CRP and P₉ is obscured by the effects of the hypertension because it predisposes both inflammation and atrial remodeling.[16,17] The effect of comorbidities predisposing to both inflammation and atrial remodeling and AF is minimal in lone AF patients and is therefore particularly interesting.

In this study, we demonstrated that the subjects with lone AF have elevated hs-CRP levels and greater values of P₉. We also found that hs-CRP was an independent risk factor of P₉. Furthermore, although hs-CRP was identified as an independent determinant of lone AF, adjustment for P₉ attenuates the relationship of hs-CRP with AF. These findings imply that P₉ may act as a mediator between inflammation and AF.

Several mechanisms might explain our observation of the association between P₉ and hs-CRP. Histological studies noted inflammatory cell infiltration and fibrosis in atrial biopsies of patients with lone AF.[18] Inflammation cell filtration and calcium overload during AF may promote oxidative damage in atrial tissue which promotes atrial fibrosis and facilitates AF continuation.[21,22] Furthermore, inflammation may initiate endothelial dysfunction and activation of rennin-angiotensin-aldosterone axis and play a part in the structural remodeling, including atrial fibrosis, loss of atrial myocytes mass. Furthermore, CRP binds to phosphocholine, recognizing phospholipids components of damaged cells and some foreign pathogens.[23]

Table 3: Univariate predictors of AF

| Variables          | OR  | 95% CI of OR | P    |
|--------------------|-----|--------------|------|
| Age                | 1.027 | 0.992–1.062  | 0.128 |
| Male               | 1.145 | 0.557–2.355  | 0.713 |
| Smoking            | 1.125 | 0.574–2.207  | 0.731 |
| Hyperlipidemia     | 0.901 | 0.369–2.203  | 0.820 |
| BMI                | 1.162 | 1.002–1.349  | 0.047 |
| Systolic blood pressure | 1.018 | 0.996–1.042  | 0.112 |
| Diastolic blood pressure | 1.018 | 0.991–1.046  | 0.194 |
| Heart rate         | 1.017 | 0.997–1.038  | 0.098 |
| Fasting glucose    | 1.544 | 0.912–2.614  | 0.106 |
| Serum creatinine   | 1.007 | 0.984–1.031  | 0.549 |
| hs-CRP             | 12.418| 5.149–29.946 | 0.000 |
| LAD                | 1.106 | 1.050–1.166  | 0.000 |
| LVEDD              | 1.110 | 1.024–1.203  | 0.011 |
| LVEF               | 0.986 | 0.936–1.039  | 0.603 |
| P₉                 | 1.223 | 1.145–1.306  | 0.000 |

AF: Atrial fibrillation; OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; hs-CRP: High-sensitive C-reactive protein; LAD: Left atrial diameter; LVEDD: Left ventricular end diastolic diameter; LVEF: Left ventricular ejection fraction; P₉: P-wave dispersion.

Table 4: Multivariate predictors of AF

| Variables          | OR  | 95% CI of OR | P    |
|--------------------|-----|--------------|------|
| LVEDD              | 1.189 | 1.063–1.332  | 0.003 |
| hs-CRP             | 15.430| 6.031–39.476 | 0.000 |
| Further adjusted for P₉ |     |              |      |
| P₉                 | 1.213 | 1.123–1.310  | 0.000 |
| hs-CRP             | 6.246 | 2.280–17.115 | 0.000 |

AF: Atrial fibrillation; OR: Odds ratio; CI: Confidence interval; LVEDD: Left ventricular end diastolic diameter; hs-CRP: High-sensitive C-reactive protein; P₉: P-wave dispersion.

In this study, we demonstrated that the subjects with lone AF have elevated hs-CRP levels and greater values of P₉. We also found that hs-CRP was an independent risk factor of P₉. Furthermore, although hs-CRP was identified as an independent determinant of lone AF, adjustment for P₉ attenuates the relationship of hs-CRP with AF. These findings imply that P₉ may act as a mediator between inflammation and AF.
CRP may activate the classic complement pathway.[11] These changes may lead to the inter- and intra-atrial conduction heterogeneity and dispersion of the atrial refractory period/velocity, providing the substrate for AF, thus may underlie the prolongation of $P_e$.

Although our results indicate an association between hs-CRP and AF, the present study was not a prospective cohort design in nature, thus, limits our ability to determine a cause or effect relationship between hs-CRP and AF. Nevertheless, the aim of the present study was to investigate the association between the inflammation and the atrial electrical remodeling in AF. Whether the inflammation was a cause or the consequence of AF remains controversial and deserves further study.

In conclusion, the present study demonstrated that in patients with lone AF, $P_e$ and hs-CRP are inter-associated and in relation to AF. The interaction between hs-CRP and AF may be mediated by $P_e$, suggesting a crucial role of inflammation in the atrial electrophysiological remodeling predisposing to AF.

**REFERENCES**

1. Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998;135:733-8.
2. Gona H, Gallagher MM, Guo XH, Yap YG, Hnatkova K, Camm AJ. P-wave abnormality predicts recurrence of atrial fibrillation after electrical cardioversion: A prospective study. Ann Noninvasive Electrocardiol 2014;19:57-62.
3. Tuluce K, Ozerkan F, Yakar Tuluce S, Yavuzgil O, Gurgun C, Bilgin M, et al. Relationships between $p$ wave duration, atrial electromechanical delay, left atrial remodeling, and NT-proBNP levels, in patients with hypertrophic cardiomyopathy. Cardiol J 2015;22:94-100.
4. Guray U, Guray Y, Mecit B, Yilmaz MB, Sasmaz H, Korkmaz S. Maximum $p$ wave duration and $p$ wave dispersion in adult patients with secundum atrial septal defect: The impact of surgical repair. Ann Noninvasive Electrocardiol 2004;9:136-41.
5. Guntekin U, Gunes Y, Tuncer M, Gunes A, Sahin M, Simsek H. Long-term follow-up of $P_e$ wave duration and dispersion in patients with mitral stenosis. Pacing Clin Electrophysiol 2008;31:1620-4.
6. Akdemir R, Ozhan H, Gunduz H, Tamer A, Yazici M, Erbilen E, et al. Effect of reperfusion on $P_e$ wave duration and $P_e$ wave dispersion in acute myocardial infarction: Primary angioplasty versus thrombolytic therapy. Ann Noninvasive Electrocardiol 2005;10:35-40.
7. Hashemi Jazi M, Amirpour A, Zavvar R, Behjati M, Gharipour M. Predictive value of $P_e$ wave duration and dispersion in post coronary artery bypass surgery atrial fibrillation. ARYA Atheroscler 2012;8:59-62.
8. Guntekin U, Gunes Y, Simsek H, Tuncer M, Arslan S. $P_e$ wave duration and dispersion in patients with hyperthyroidism and the short-term effects of antithyroid treatment. Indian Pacing Electrophysiol J 2009;9:251-9.
9. Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med 2012;106:1134-8.
10. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10.
11. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardeveld FW, de Beaumont EM, et al. Activation of the complement system during and after cardiopulmonary bypass surgery. Postoperative activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997;96:3542-8.
12. Barassi A, Pezzilli R, Morselli-Labate AM, Lombardi F, Belletti S, Dogliotti G, et al. Serum amyloid A and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can J Cardiol 2012;28:537-41.
13. Lin YJ, Tsao HM, Chang SL, Lo LW, Tuan TC, Hu YF, et al. Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation. Am J Cardiol 2010;105:495-501.
14. Conway DS, Buggins P, Hughes E, Lip GY. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal echocardiographic findings in atrial fibrillation. Am J Cardiol 2004;93:1368-73, A6.
15. Tsoufis C, Syresloudis D, Hatzziyianni A, Tszamou V, Andriokou I, Tolic P, et al. Relationships of CRP and $P_e$ wave dispersion with atrial fibrillation in hypertensive subjects. Ann J Hypertens 2010;23:202-7.
16. Tsoufis C, Syresloudis D, Dimitriadis K, Thomopoulos C, Tsiachris D, Pavlidis P, et al. Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension. J Hum Hypertens 2008;22:501-8.
17. Emiroglu MY, Bulut M, Sahin M, Acar G, Akcakoyun M, Kargin R, et al. Assessment of atrial conduction time in patients with essential hypertension. J Electrocardiol 2011;44:251-6.
18. Frustaci A, Chimenti C, Bellocchi F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4.
19. Kamagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004;62:105-11.
20. Sata N, Hamada N, Horinouchi T, Amitani S, Yamashita T, Moriyama Y, et al. Disturbed atrial electrophysiological remodeling in patients with lone atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014;130:1847-58.
21. Harada M, Van Wagoner DR, Nattel S. Role of inflammation in atrial fibrillation. Circulation 2014;130:1847-58.